Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2011 Oct 1;29(28):3747-52.
doi: 10.1200/JCO.2010.34.0778. Epub 2011 Aug 29.

Risk of Breast Cancer in Women With a CHEK2 Mutation With and Without a Family History of Breast Cancer

Affiliations
Multicenter Study

Risk of Breast Cancer in Women With a CHEK2 Mutation With and Without a Family History of Breast Cancer

Cezary Cybulski et al. J Clin Oncol. .

Abstract

Purpose: To estimate the risk of breast cancer in a woman who has a CHEK2 mutation depending on her family history of breast cancer.

Patients and methods: Seven thousand four hundred ninety-four BRCA1 mutation-negative patients with breast cancer and 4,346 control women were genotyped for four founder mutations in CHEK2 (del5395, IVS2+1G>A, 1100delC, and I157T).

Results: A truncating mutation (IVS2+1G>A, 1100delC, or del5395) was present in 227 patients (3.0%) and in 37 female controls (0.8%; odds ratio [OR], 3.6; 95% CI, 2.6 to 5.1). The OR was higher for women with a first- or second-degree relative with breast cancer (OR, 5.0; 95% CI, 3.3 to 7.6) than for women with no family history (OR, 3.3; 95% CI, 2.3 to 4.7). If both a first- and second-degree relative were affected with breast cancer, the OR was 7.3 (95% CI, 3.2 to 16.8). Assuming a baseline risk of 6%, we estimate the lifetime risks for carriers of CHEK2 truncating mutations to be 20% for a woman with no affected relative, 28% for a woman with one second-degree relative affected, 34% for a woman with one first-degree relative affected, and 44% for a woman with both a first- and second-degree relative affected.

Conclusion: CHEK2 mutation screening detects a clinically meaningful risk of breast cancer and should be considered in all women with a family history of breast cancer. Women with a truncating mutation in CHEK2 and a positive family history of breast cancer have a lifetime risk of breast cancer of greater than 25% and are candidates for magnetic resonance imaging screening and for tamoxifen chemoprevention.

Comment in

Similar articles

See all similar articles

Cited by 47 articles

See all "Cited by" articles

Publication types

Substances

Feedback